Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Switch to English

10604	Sociétés
225013	Mots-clés
153734	Articles
119072	Communiqués

Accueil
Sociétés
Moderna, Inc.

COMMUNIQUÉ DE PRESSE

publié le 01/02/2024 à 13:00, il y a 2 années 4 mois

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
COMMUNIQUÉ DE PRESSE

publié le 31/01/2024 à 23:45, il y a 2 années 4 mois

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
COMMUNIQUÉ DE PRESSE

publié le 08/01/2024 à 13:00, il y a 2 années 5 mois

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
COMMUNIQUÉ DE PRESSE

publié le 20/12/2023 à 22:05, il y a 2 années 6 mois

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
COMMUNIQUÉ DE PRESSE

publié le 15/12/2023 à 00:00, il y a 2 années 6 mois

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
COMMUNIQUÉ DE PRESSE

publié le 14/12/2023 à 12:30, il y a 2 années 6 mois

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
COMMUNIQUÉ DE PRESSE

publié le 12/12/2023 à 14:00, il y a 2 années 6 mois

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
COMMUNIQUÉ DE PRESSE

publié le 07/12/2023 à 13:00, il y a 2 années 6 mois

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
COMMUNIQUÉ DE PRESSE

publié le 14/11/2023 à 13:00, il y a 2 années 7 mois

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
COMMUNIQUÉ DE PRESSE

publié le 08/11/2023 à 22:15, il y a 2 années 7 mois

Moderna to Present at Upcoming Conferences in November 2023

Les Echos

Publié le 19/06/2026 à 19:33, il y a 1 jour 13 heures

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Publié le 19/06/2026 à 19:33, il y a 1 jour 13 heures

Disclosure of transactions in own shares from June 15 to June 19, 2026
Publié le 19/06/2026 à 19:23, il y a 1 jour 13 heures

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Publié le 19/06/2026 à 19:23, il y a 1 jour 13 heures

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Publié le 19/06/2026 à 19:05, il y a 1 jour 13 heures

CP - Changement de gouvernance

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 20/06/2026 à 01:00, il y a 1 jour 7 heures

Onco-Innovations Announces Non-Brokered LIFE Offering
Publié le 20/06/2026 à 00:00, il y a 1 jour 8 heures

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Publié le 19/06/2026 à 04:30, il y a 2 jours 4 heures

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Publié le 19/06/2026 à 01:20, il y a 2 jours 7 heures

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Publié le 19/06/2026 à 01:07, il y a 2 jours 7 heures

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

Voir tout ACCESSWIRE

EQS Group

Publié le 20/06/2026 à 21:25, il y a 11 heures 20 minutes

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Publié le 20/06/2026 à 06:00, il y a 1 jour 2 heures

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Publié le 19/06/2026 à 20:17, il y a 1 jour 12 heures

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Publié le 19/06/2026 à 20:17, il y a 1 jour 12 heures

2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Publié le 19/06/2026 à 19:01, il y a 1 jour 13 heures

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting